Business Context and Reporting Period
This Form 6-K filing by James Hardie Industries Plc covers the month of April 2018, with the report signed on April 4, 2018. The registrant is a foreign private issuer headquartered in Dublin, Ireland, and files annual reports on Form 20-F.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a notification of a corporate event rather than a financial results report.
Material Changes
The primary material change disclosed in this filing is the completion of the acquisition of Fermacell. This transaction is detailed in Exhibit 99.1 attached to the report.
Guidance, Outlook, and Risks
The filing contains extensive forward-looking statements regarding future performance, capital expenditures, credit facilities, and dividend expectations. Management highlights several key risks and contingencies that could cause actual results to differ from projections:
- Asbestos Liabilities: Risks related to prior asbestos manufacturing, including contributions to the Asbestos Injuries Compensation Fund (AICF), potential shortfalls, and currency exchange impacts on recorded liabilities.
- Acquisition Integration: Risks associated with the consummation and integration of the Fermacell acquisition.
- Market and Economic Conditions: Dependence on residential and commercial construction markets, housing values, interest rates, and economic conditions in the US and Asia Pacific regions.
- Legal and Regulatory: Exposure to product liability, environmental, and competition law matters, as well as changes in tax laws.
- Operational Risks: Supply and cost of raw materials, weather patterns, and reliance on a concentrated customer base.
Investor Verification Checklist
- Verify the terms and financial impact of the completed Fermacell acquisition via Exhibit 99.1.
- Review the "Risk Factors" section of the Form 20-F filed on May 18, 2017, for detailed disclosures on asbestos liabilities and legal proceedings.
- Monitor future filings for specific financial results and integration updates regarding Fermacell.
- Assess the status of the Asbestos Injuries Compensation Fund (AICF) and any required contributions.